Results 91 to 100 of about 11,689 (208)
Safety and reactogenicity of COVID-19 vaccines
, 2021 The Australian Government has detailed a national rollout strategy for the delivery of COVID-19 vaccines. In the Phase 1a, vaccines will be available to quarantine and border workers, priority sub-groups of frontline health workers, and aged care and ...
Marnie, C., Peters, M.
core
Medical Journal of Australia, Volume 224, Issue 6, June 2026.ABSTRACT Objective This study quantifies the short‐term risk profiles of seven severe acute respiratory syndrome coronavirus 2 virus (SARS‐CoV‐2) vaccines—Comirnaty Bivalent BA.1, Comirnaty Bivalent BA.4‐5, Comirnaty XBB.1.5, Spikevax Bivalent BA.1, Spikevax Bivalent BA.4‐5, Spikevax XBB.1.5 and Nuvaxovid—administered as booster doses in Australia ...
Evelyn Tay +9 more
wiley +1 more source
Can reactogenicity predict immunogenicity after COVID-19 vaccination?
, 2021 Background/Aims This study aimed to assess the association between local and systemic reactogenicity and humoral immunogenicity after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination.
Su-Jin Choi +21 more
core +1 more source
Perspectives on Pertussis Prevention
Acta Paediatrica, EarlyView.
Ulrich Heininger
wiley +1 more source
Local reactogenicity following rAd5 vaccine.
, 2014 All subjects who received rAd5 vaccination by needle injection (n = 15) or by Biojector injection (n = 16) were counted once at worst severity over 5 days for solicited local parameters.
Julie E. Ledgerwood (253787) +11 more
core +1 more source
In vivo CAR therapies: Turning the patient into their own CAR factory
HemaSphere, Volume 10, Issue 5, May 2026.Abstract Over the past decade, ex vivo autologous chimeric antigen receptor (CAR)‐T‐cell therapies have reshaped the treatment of B‐cell malignancies. Despite their remarkable clinical efficacy, their application remains limited by complex manufacturing processes, demanding logistics, long turnaround times, and substantial costs. In vivo CAR approaches
François Vilcot +3 more
wiley +1 more source
Assessing the Reactogenicity of Homologous and Heterologous COVID-19 Vaccine Schedules
, 2023 Introduction: COVID-19 vaccines were considered as the most effective mode to prevent morbidity and mortality from COVID-19. However, similar to other vaccines, adverse events post-vaccination is expected.
Teejay Anthony Santos (11364411)
core +1 more source
Frontiers in Immunology, 2020 Insights into the potential candidate hub genes may facilitate the generation of safe and effective immunity against seasonal influenza as well as the development of personalized influenza vaccines for the elderly at high risk of influenza virus ...
Jing Yang +17 more
doaj +1 more source
Medicinal Research Reviews, Volume 46, Issue 3, Page 672-712, May 2026.ABSTRACT Respiratory syncytial virus (RSV) is a common virus that causes respiratory infections, posing a serious threat, particularly to infants, the elderly, and individuals with compromised immune systems. As the leading cause of lower respiratory tract infections (LRTIs) in infants, RSV is responsible for millions of cases worldwide each year.
Jie Shi +6 more
wiley +1 more source
VaccinesEnhancing our comprehension of mRNA vaccines may facilitate the future design of novel vaccines aimed at augmenting immune protection while minimising reactogenic responses. Before this design is carried out, it is important to determine whether adaptive
Joaquín Sáez-Peñataro +6 more
doaj +1 more source